277 related articles for article (PubMed ID: 21750178)
1. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.
Lovejoy DB; Jansson PJ; Brunk UT; Wong J; Ponka P; Richardson DR
Cancer Res; 2011 Sep; 71(17):5871-80. PubMed ID: 21750178
[TBL] [Abstract][Full Text] [Related]
2. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
Gundelach JH; Madhavan AA; Wettstein PJ; Bram RJ
FASEB J; 2013 Feb; 27(2):782-92. PubMed ID: 23134680
[TBL] [Abstract][Full Text] [Related]
3. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
Jansson PJ; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2010 Aug; 53(15):5759-69. PubMed ID: 20597487
[TBL] [Abstract][Full Text] [Related]
4. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
Gutierrez E; Richardson DR; Jansson PJ
J Biol Chem; 2014 Nov; 289(48):33568-89. PubMed ID: 25301941
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism.
Merlot AM; Pantarat N; Menezes SV; Sahni S; Richardson DR; Kalinowski DS
Mol Pharmacol; 2013 Dec; 84(6):911-24. PubMed ID: 24085840
[TBL] [Abstract][Full Text] [Related]
6. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
Gutierrez EM; Seebacher NA; Arzuman L; Kovacevic Z; Lane DJ; Richardson V; Merlot AM; Lok H; Kalinowski DS; Sahni S; Jansson PJ; Richardson DR
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1665-81. PubMed ID: 27102538
[TBL] [Abstract][Full Text] [Related]
8. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
Krishan S; Richardson DR; Sahni S
Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
[TBL] [Abstract][Full Text] [Related]
9. Complex forming competition and in-vitro toxicity studies on the applicability of di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) as a metal chelator.
Gaál A; Orgován G; Polgári Z; Réti A; Mihucz VG; Bősze S; Szoboszlai N; Streli C
J Inorg Biochem; 2014 Jan; 130():52-8. PubMed ID: 24176919
[TBL] [Abstract][Full Text] [Related]
10. Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition.
Ismail M; Yang W; Li Y; Wang Y; He W; Wang J; Muhammad P; Chaston TB; Rehman FU; Zheng M; Lovejoy DB; Shi B
Biomaterials; 2022 Oct; 289():121760. PubMed ID: 36044788
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
12. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
[TBL] [Abstract][Full Text] [Related]
13. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
Lovejoy DB; Sharp DM; Seebacher N; Obeidy P; Prichard T; Stefani C; Basha MT; Sharpe PC; Jansson PJ; Kalinowski DS; Bernhardt PV; Richardson DR
J Med Chem; 2012 Aug; 55(16):7230-44. PubMed ID: 22861499
[TBL] [Abstract][Full Text] [Related]
14. Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
Stacy AE; Palanimuthu D; Bernhardt PV; Kalinowski DS; Jansson PJ; Richardson DR
J Med Chem; 2016 Sep; 59(18):8601-20. PubMed ID: 27524608
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
[TBL] [Abstract][Full Text] [Related]
16. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
Seebacher NA; Richardson DR; Jansson PJ
Cell Death Dis; 2016 Dec; 7(12):e2510. PubMed ID: 27906178
[TBL] [Abstract][Full Text] [Related]
17. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
[TBL] [Abstract][Full Text] [Related]
18. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
[TBL] [Abstract][Full Text] [Related]
19. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
20. Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization.
Stefani C; Al-Eisawi Z; Jansson PJ; Kalinowski DS; Richardson DR
J Inorg Biochem; 2015 Nov; 152():20-37. PubMed ID: 26335599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
